Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...
Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback